Skip to Content

Fidelity Select Biotechnology FBIOX

Medalist Rating as of | See Fidelity Investment Hub
  • NAV / 1-Day Return 19.01  /  −1.09 %
  • Total Assets 4.9 Bil
  • Adj. Expense Ratio
    0.720%
  • Expense Ratio 0.720%
  • Distribution Fee Level Low
  • Share Class Type No Load
  • Category Health
  • Investment Style Mid Blend
  • Min. Initial Investment
  • Status Open
  • TTM Yield 0.41%
  • Turnover 51%

USD | NAV as of Mar 18, 2024 | 1-Day Return as of Mar 18, 2024, 10:14 PM GMT+0

Morningstar’s Analysis FBIOX

Will FBIOX outperform in future?

Get our overall rating based on a fundamental assessment of the pillars below.

Fidelity Select Biotechnology’s Process Pillar rating is Average, but a strong management team still helps this strategy retain its Morningstar Medalist Rating of Bronze.

null Morningstar Manager Research

Morningstar Manager Research

Summary

The portfolio maintains a cost advantage over competitors, priced within the second-lowest fee quintile among peers.

Rated on Published on

Unlock our full analysis with Morningstar Investor

Portfolio Holdings FBIOX

  • Current Portfolio Date
  • Equity Holdings
  • Bond Holdings
  • Other Holdings
  • % Assets in Top 10 Holdings 45.8
Top 10 Holdings
% Portfolio Weight
Market Value USD
Sector

AbbVie Inc

13.23 610.2 Mil
Healthcare

Amgen Inc

8.70 401.3 Mil
Healthcare

Krystal Biotech Inc

4.79 220.8 Mil
Healthcare

Regeneron Pharmaceuticals Inc

4.22 194.8 Mil
Healthcare

Vertex Pharmaceuticals Inc

4.00 184.8 Mil
Healthcare

Gilead Sciences Inc

2.54 117.0 Mil
Healthcare

Alnylam Pharmaceuticals Inc

2.45 113.1 Mil
Healthcare

Biogen Inc

2.18 100.4 Mil
Healthcare

Ascendis Pharma A/S ADR

1.86 85.7 Mil
Healthcare

Apellis Pharmaceuticals Inc

1.84 84.8 Mil
Healthcare